FIGURE 6.

Eltanexor treatment enhances a type I IFN response in HCMV-infected or poly (I:C) treated HFFs. (A) Transcriptional levels of IFN-β in HCMV infected cells treated with Eltanexor or DMSO were determined by RT-qPCR. HFFs were infected with HCMV at a MOI = 1, and treated with Eltanexor (0.4 μM) or DMSO. IFN-β mRNA levels were quantified by RT-qPCR at the indicated timepoints and normalized to cellular β-actin. Fold changes of IFN-β in DMSO-treated samples at 6 hpi were normalized to 1 (arbitrary unit). Data represent mean ± SEM, n = 3. (B) Eltanexor increase the transcriptional levels of IFN-β in poly(I:C) treated cells. HFFs were treated with DMSO, Eltanexor (0.4 μM), poly(I:C) (20μg/mL), or Eltanexor and poly(I:C). mRNA levels of IFN-β were quantified by RT-qPCR at the indicated timepoints and normalized to cellular β-actin. Data represent mean ± SEM, n = 3. (C) The production of IFN-β in the culture supernatants from HCMV infected or Poly (I:C) treated HFFs was determined by ELISA at the indicated timepoints. Data represent mean ± SEM, n = 3. (D) Expression of ISG15 and ISG54 in HCMV infected HFFs with or without Eltanexor treatment. Cells were infected with HCMV (MOI = 1) and treated with Eltanexor (0.4 μM) or vehicle DMSO. Transcript levels of ISG15 and ISG54 were determined by RT-qPCR at the indicated timepoints. Fold changes of transcripts in HCMV infected cells at 24 hpi were normalized to 1 (arbitrary unit). Data represent mean ± SEM, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001.